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The International Agency for Research on Cancer has declared
smoking to be a risk factor for hepatocellular carcinoma (HCC).
However, passive exposure to cigarette smoke and use of nonci-
garette tobacco products on the risk of HCC has not been exam-
ined. Therefore, we evaluated the independent effects of different
types of smoking exposure along with multiple risk factors for
HCC and determined whether the magnitude of smoking was
modiﬁed by other risk factors in men and women. We conducted a
case-control study at The University of Texas M. D. Anderson
Cancer Center where 319 HCC patients and 1,061 healthy control
subjects were personally interviewed for several HCC risk factors.
Multivariate logistic regression analysis was performed to esti-
mate the adjusted odds ratio (AOR) and 95% conﬁdence interval
(CI) for each potential risk factor. Use of smokeless tobacco
(chewing tobacco and snuff), cigars, pipes and passive smoking ex-
posure were not related to HCC among noncigarette smokers.
However, regular cigarette smoking was associated with HCC in
men: AOR, 1.9 (95% CI, 1.1–3.1). Heavy alcohol consumption was
associated with HCC in women: AOR, 7.7 (95% CI, 2.3–25.1).
Cigarette smoking interacted synergistically with chronic infec-
tion of hepatitis C virus in men: AOR, 136.3 (95% CI, 43.2–429.6)
and with heavy alcohol consumption in women: AOR, 13.7 (95%
CI, 3.2–57.9). We conclude that sex differences were observed in
HCC relationship with cigarette smoking and alcohol consump-
tion. Controlling for smoking exposure might be a prudent
approach to the prevention of HCC, especially in patients with
chronic viral hepatitis infections.
' 2008 Wiley-Liss, Inc.
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The incidence of hepatocellular carcinoma (HCC) has increased
signiﬁcantly in the United States over the past 2 decades.1 Chronic
hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
are the most established risk factors.2 However, in the United
States, approximately 60% of HCC cases are not attributable to
hepatitis viral infection.3 Additional risk factors—such as heavy
alcohol consumption, diabetes and cigarette smoking—have been
linked to the etiology of HCC.3–18
Smoking prevalence in the United States has declined since
1997; however, despite the overwhelming evidence of smoking’s
harmful effects, almost 22% of U.S. adults still smoked cigarettes
in 2000.19 This prevalence may have disproportionately wide-
spread implications in the etiology of different malignancies. The
association between smoking and HCC was demonstrated by the
results of a meta-analysis of 14 studies, which revealed that ciga-
rette smoking signiﬁcantly elevated the overall risk of developing
HCC (p 5 0.001).20 Moreover, a dose-response effect was
reported in 11 studies, with an overall summary odds ratio (OR) of
2.6 (95% conﬁdence interval [CI], 2.1–3.3; p 5 0.001) for heavy
smokers. In support of this association, the International Agency
for Research on Cancer of the World Health Organization recently
declared smoking to be a risk factor for liver cancer.21
As cigarette smoking has declined in popularity, the use of
cigars, pipes and nonsmoked tobacco has been increasing in the
United States.22 Men who exclusively smoke cigars and/or pipes
have a higher risk of cancer of the larynx, lung and oral cavity.23–26
During smoking of cigarettes, cigars, pipes and other tobacco
products, not only mainstream smoke is inhaled by the smoker,
but a side stream of smoke is also released into the air; a smoker
inhales only 15% of a cigarette’s smoke—the rest goes into the
surrounding air.27 Once released, this side-stream smoke is mixed
with exhaled mainstream smoke; together, they make up second-
hand tobacco smoke, also referred to as ‘‘involuntary,’’ ‘‘environ-
mental’’ or ‘‘passive’’ smoke, to which both smokers and non-
smokers are exposed. The association between passive smoking
and lung cancer has been conﬁrmed by several meta-analyses.28–30
However, the association between passive smoking and breast
cancer, childhood cancers and renal cell carcinoma is inconclu-
sive.21 Despite evidence sufﬁcient to judge the positive association
between active smoking and liver cancer, smoking-HCC relation-
ship in men and women separately has not been widely addressed
by epidemiological studies. In addition, no previous studies have
examined the impact of passive smoking on HCC. To further
assess the associations between the risk of HCC and passive smok-
ing and the use of noncigarette tobacco products, we embarked on
this large-scale case-control study, taking into consideration the
confounding effect of cigarette smoking and other signiﬁcant risk
factors for HCC.
Material and methods
Study design and population
This was a hospital-based case-control study in which case
patients and control subjects were prospectively ascertained. The
study was approved by the Institutional Review Board of The Uni-
versity of Texas M. D. Anderson Cancer Center. Written informed
consent for an interview and for a biological sample was obtained
from each participant. A total of 1,380 subjects (319 case patients
with HCC and 1,061 healthy control subjects) were enrolled.
Case patients were recruited from the population of patients
with newly diagnosed HCC who were evaluated and treated at the
institution’s gastrointestinal medical and surgical oncology outpa-
tient clinics. Inclusion criteria were as follows: a pathologically
conﬁrmed diagnosis of HCC, U.S. residency and the ability to
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communicate in English. Patients with concurrent or past history
of other types of cancers were excluded.
From January 2000 through December 2006, 470 patients with
suspected HCC were approached, 390 eligible patients were iden-
tiﬁed and 319 patients were enrolled (Fig. 1). We failed to recruit
71 eligible patients (71/390 [18.2%]) for the following reasons:
patient refusal (30%), physician refusal (n 5 5%), severity of ill-
ness or sadness of the patient or family (19%), language barrier
(19%), inadequate time to complete interview (8%) and change in
the patient’s schedule (19%). The clinical characteristics, demo-
graphic features and medical histories of these unrecruited patients
were retrieved from their medical records and recorded in a data-
base. Statistical analysis indicated that the unrecruited patients did
not differ from enrolled patients in terms of stage of disease, age,
sex, educational level, state of residency, race/ethnicity, smoking
and alcohol exposure or hepatitis virus reactivity.
Control subjects were healthy nonblood relatives, particularly
spouses, of patients with cancers other than liver, gastrointestinal,
lung or head and neck (smoking-related cancers) who were under-
going treatment at our institution. Eligibility criteria for control
subjects were the same as those for patients, except that control
subjects could not have ever had cancer. A short, structured ques-
tionnaire was used to screen potential control subjects on the basis
of eligibility criteria. Control subjects and patients were recruited
simultaneously.
Of potential control subjects, 81.9% agreed to participate. There
were no signiﬁcant differences in age, sex, race/ethnicity, educa-
tional level or accompanied patient’s type of cancer between those
who consented and those who refused to participate.
Case patients and control subjects were personally interviewed
by well-trained interviewers; no proxy interviews were conducted.
The interviewers used a structured and validated questionnaire to
collect information about demographic characteristics and poten-
tial risk factors for HCC such as personal smoking history, alcohol
use, medical history, occupational history and family history of
cancer.
Cigarette smokers were deﬁned as subjects who had smoked
100 cigarettes during their lifetimes. Former smokers were
deﬁned as subjects who had quit smoking at least 1 year before
study enrollment. Former and current smokers were asked to indi-
cate the average number of cigarettes they smoked per day, the
age at which they began smoking and the duration of smoking.
Former smokers were questioned about the age at which they
stopped smoking. Pack-years were estimated by multiplying the
number of years of smoking and the number of packs of cigarettes
smoked per day (1 pack-year 5 1 pack of cigarettes/day for a
year). Heavy smokers were deﬁned as those who had >20 pack-
years of smoking.
Subjects were also asked about their use of pipes, cigars and
smokeless tobacco products (chewing tobacco and snuff). Fre-
quency of daily intake (times per day) and duration of exposure to
each type (years of use) were documented for each subject. The
total intake-years of exposure were calculated by multiplying
daily intake by duration of exposure for each tobacco type for all
users. Participants were then classiﬁed according to total intake-
years of exposure; the median value of intake-years of exposure
for control subjects was used as a cutoff point to discriminate
between heavy users (greater than the median value) and mild/
moderate users (less than or equal to the median value).
Case patients and control subjects were asked about their his-
tory of passive smoking during childhood (birth to 18 years),
adulthood at home (age >18 years) and adulthood at work. For
exposed individuals, the starting age or year of exposure and end-
ing age or year of exposure were recorded for each period. The cu-
mulative duration of passive smoking was estimated by summing
the duration of exposure for the 3 periods after controlling for pos-
sible overlap between exposure during adulthood at home and
adulthood at work. Exposed individuals were then classiﬁed
according to cumulative life-years of passive smoking. Informa-
tion on passive smoking was incomplete for 3 control subjects;
statistical analysis was performed on data from 319 case patients
and 1,058 control subjects.
FIGURE 1 – Flow diagram showing ascertainment of US eligible cases who were patients with pathologically diagnosed hepatocellular carci-
noma at The University of Texas M. D. Anderson Cancer Center (2000–2006).
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Alcohol drinkers were deﬁned as subjects who had consumed at
least 4 alcoholic drinks of beer, wine or hard liquor each month
for 6 months during their lifetimes. The age at which drinking
started and (if applicable) ended were recorded for each type of
alcoholic beverage for all participants. Drinkers were further clas-
siﬁed according to the total lifetime volume of ethanol consumed
in milliliters, which was computed according to the frequency of
drinking, type of serving (glass, bottle or can), number and size of
each serving and duration of consumption, summed over the
whole period of alcohol use. Consumed serving units were
deﬁned as 12.0 oz for beer, 4.0 oz for wine and 1.5 oz for hard
liquor (each equivalent to approximately 12.0 mL of ethanol).31
Heavy alcohol consumption was deﬁned as consumption of more
than 60 mL ethanol/day during the subject’s period of alcohol
drinking.32,33
Ten milliliters of blood was drawn from a peripheral vein for
each participant. The samples were tested for the presence of anti-
HCV antibodies (anti-HCV) using a third-generation enzyme-
linked immunosorbent assay (Abbott Laboratories, North Chicago,
IL). The samples were also tested using the enzyme-linked immu-
nosorbent assay for the presence of HBV surface antigen (HBsAg)
and HBV core antibody (anti-HBc). Plasma samples were avail-
able for only 889 control subjects who were tested for virus
markers with all HCC patients.
Statistical methods
Microsoft Access software was used for data entry and data
management, and Stata software (Stata, College Station, TX) was
used for statistical analysis. Chi-square tests were used to assess
the signiﬁcance of differences in the distributions of categorical
variables between case patients and control subjects. We per-
formed univariate single-factor unconditional logistic regression
analyses to assess the marginal effects of each HCC risk factor
using maximum-likelihood estimation. We also performed multi-
variate unconditional logistic regression analyses using all varia-
bles that were signiﬁcant at p < 0.05 in the single-factor analyses.
For each factor, we calculated the adjusted OR (AOR) and 95%
CI using maximum-likelihood estimation. All AORs were
adjusted for age, sex, race/ethnicity, education, marital status,
place of residency and other signiﬁcant HCC risk factors by use of
the likelihood-ratio test. The ﬁnal model was chosen on the basis
of biological plausibility and lowest -2 Log Likelihood function.
Using the additive scale, we investigated possible interactions
between signiﬁcant risk factors. To assess deviations from the
additive model (which assumes that there is no interaction
between variables), we calculated the synergism index [S 5 (OR11
2 1/([OR011 OR10)2 2, where OR11 is the OR of the joint effect
of 2 risk factors and OR10 and OR01 is the OR of each risk factor
in the absence of the other], and its 95% CI. A value of S equal to
unity was interpreted to be indicative of additivity, whereas a
value greater than unity was indicative of superadditivity and
synergism.34
Results
Participants characteristics
Table I shows the distribution of case patients and control sub-
jects according to demographic characteristics. Most study sub-
jects were male and non-Hispanic white. Case patients were
slightly older than control subjects, with a mean difference 6
standard deviation of 2.2 6 0.7 years (case patients, 62 6 0.7;
control subjects, 60 6 0.3 years). Case patients also had a lower
education level. In the multivariate logistic regression analysis, we
adjusted for all signiﬁcant demographic variables. Stratiﬁed analy-
sis by gender was performed to examine HCC risk factors in men
and women separately.
Risk factors for HCC
Nonsmoking risk factors. Large, statistically signiﬁcant differ-
ences in the prevalence of anti-HCV, HBsAg, anti-HBc positivity
were observed between case patients and control subjects (p <
0.0001). Multivariate AORs for the association of HCC with anti-
HCV and HCC with HBsAg were statistically signiﬁcant in both
men and women. However, the multivariate AOR for anti-HBc
and HCC was not statistically signiﬁcant in women (Table II).
The mean lifetime intake of ethanol was 730,853.8 mL in case
patients and 291,350.8 mL in control subjects (p5 0.0001); a sim-
ilar difference between case patients and control subjects was
TABLE I – CHARACTERISTICS OF STUDY PARTICIPANTS
Demographic variable
Cases Controls
p-Value
N5 319 % (95% CI) N 5 1,061 % (95% CI)
Sex 0.02
Male 225 70.5 (65.2–75.5) 670 63.1 (60.2–66.1)
Female 94 29.5 (24.5–34.8) 391 36.9 (34.0–39.8)
Age (years) 0.004
40 15 4.7 (2.7–7.6) 46 4.3 (3.2–5.7)
41–50 39 12.2 (8.8–16.3) 176 16.6 (14.4–19.0)
51–59 89 27.9 (23.0–33.2) 313 29.5 (26.8–32.3)
60–69 91 28.5 (23.6–33.8) 342 32.2 (29.4–35.1)
70 85 26.7 (21.9–31.9) 184 17.4 (15.1–19.8)
Ethnicity 0.001
White 215 67.4 (62.0–72.5) 939 88.5 (86.4–90.4)
African Americans 31 9.7 (6.7–13.5) 40 3.8 (2.7–5.1)
Hispanics 49 15.4 (11.6–19.8) 74 7.0 (5.5–8.7)
Asians 24 7.5 (4.9–11.0) 8 0.7 (0.3–1.5)
Educational level 0.001
High school degree 154 48.3 (42.7–53.9) 316 29.8 (27.0–32.6)
Some college years 68 21.3 (17.0–26.2) 274 25.8 (23.2–28.6)
College degree 97 30.4 (25.4–35.8) 471 44.4 (41.4–47.4)
Marital status 0.001
Married/lived like married 243 76.2 (71.1–80.7) 952 89.7 (87.7–91.5)
Single 19 6.0 (3.6–9.1) 17 1.6 (0.9–2.6)
Widow 23 7.2 (4.6–10.6) 27 2.6 (1.7–3.7)
Divorced/separated 34 10.6 (7.5–14.6) 65 6.1 (4.8–7.7)
Residency by USA state 0.5
Texas and neighboring states1 234 73.3 (68.1–78.1) 760 71.6 (68.8–74.3)
Other sates 85 26.7 (21.9–31.9) 301 28.4 (25.7–31.2)
1Neighboring states included NM, LA, AR and OK.
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observed in men (p < 0.01) and women (p 5 0.01). A signiﬁcant
effect of heavy alcohol consumption on elevated risk of HCC was
observed in both men and women. However, the magnitude of the
measurement for association was larger in women (AOR 5 7.7)
than in men (AOR 5 1.8), Table II. As compared to nondrinking
men, AORs (95% CIs) were 5.2 (1.6–17.4), 0.7 (0.4–1.3) and 2.1
(1.1–4.1) for heavy drinking women, nondrinking women and
heavy drinking men, respectively. The estimated S index for inter-
action between heavy drinking and female sex 5 5.3 (95% CI,
3.6–6.8). Mild or moderate drinking (<60 mL/day) had no signiﬁ-
cant effect on HCC development in men or women.
Table II shows that patients with diabetes mellitus had a risk of
HCC 4.5 times greater than that of patients without diabetes. How-
ever, 13.9% of case patients (n 5 15) and 26.6% (n 5 29) of
control subjects had diabetes ﬁrst diagnosed at the time of cancer
diagnosis or recruitment in the study. When time of diabetes
diagnosis was considered, the estimated multivariate AORs for
patients with a history of diabetes for >1 year were 4.7 (95% CI,
3.1–7.3), 4.8 (95% CI, 2.9–8.1) and 5 (95% CI, 2.2–11.6) in all
subjects, in men and in women, respectively.
Table II also shows that a family history of cancer was associ-
ated with a signiﬁcantly elevated risk of HCC. The effect of a fam-
ily history of cancer was signiﬁcant in men (AOR 5 1.6; 95% CI,
1.1–2.5) than in women (AOR 5 1.1; 95% CI, 0.6–2.1) after con-
trolling for other signiﬁcant risk factors.
Cigarette smoking. Table III shows that cigarette smoking was
a signiﬁcant risk factor for HCC. This relationship was observed
among regular smokers (but not among irregular smokers) and
among men (but not women). Control subjects started smoking at
an earlier age than case patients (mean 6 standard error [SE] age,
19 6 0.5 years for case patients and 18 6 0.2 years for control
subjects; p 5 0.03). However, the overall duration of smoking
was longer in case patients than control subjects (mean 6 SE du-
ration, 30.9 61.8 years for case patients and 27.1 6 1.1 years for
TABLE II – RISK FACTORS OF HCC: AOR (95% CI)1 USING MULTIVARIABLE LOGISTIC REGRESSION
Smoking variable
Total population Men Women
Cases/controls AOR (95% CI) Cases/controls AOR (95% CI) Cases/controls AOR (95% CI)
HCV2 319/1,061 225/670 94/391
Anti-HCV2 219/880 1 144/533 1 75/347 1
Anti-HCV1 100/9 41.1 (18.9–89.7) 81/7 46.3 (18.4–116.3) 19/2 41.5 (8.8–195.3)
HBV2
HBsAg2/Anti-HBc2 248/859 1 171/523 1 77/336 1
HBsAg1/Anti-HBc1 25/1 6.7 (2.2–20.3) 18/1 4.1 (1.1–16.3) 7/0
HBsAg2/Anti-HBc1 46/29 2.7 (1.4–5.2) 36/16 3.7 (1.6–8.6) 10/13 1.5 (0.5–5.1)
Diabetes mellitus
No 211/952 1 140/586 1 71/366 1
Yes 108/109 4.5 (3–6.6) 85/84 4.9 (3.1–7.9) 23/25 3.8 (1.8–8.2)
1 year diabetes 15/29 3.1 (1.5–6.6) 12/20 4.6 (1.9–10.9) 3/9 1.5 (0.3–7.2)
>1 year diabetes 93/80 4.7 (3.1–7.3) 73/64 4.8 (2.9–8.1) 20/16 5 (2.2–11.6)
Alcohol drinking
No 114/463 1 58/205 1 56/258 1
Yes 205/598 1.8 (1.1–3.2) 167/465 0.9 (0.5–1.4) 38/133 1.9 (1.1–3.4)
Ethanol consumption/day3
<60 mL/day 134/530 1.1 (0.7–1.5) 106/405 0.7 (0.4–1.2) 28/125 1.5 (0.8–2.9)
60 mL/day 69/65 2.7 (1.5–4.7) 59/57 1.8 (1.1–3.4) 10/8 7.7 (2.3–25.1)
Family history of cancer
Never 103/333 1 77/232 1 26/101 1
Ever 216/728 1.5 (1.1–2.1) 148/438 1.6 (1.1–2.5) 68/290 1.1 (0.6–2.1)
1Odds ratios were adjusted for age, sex, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy alcohol consumption,
cigarette smoking and family history of cancer.–2Hepatitis virus markers were missing in 172 controls (130 men and 42 women).–3Total ethanol
intake could not be determined in 2 HCC men and 3 control men.
TABLE III – SMOKING AND RISK FOR HCC: AOR (95% CI)1 USING MULTIVARIABLE LOGISTIC REGRESSION
Smoking variable
Total population1 Men2 Women2
Cases/controls AOR (95% CI) Cases/controls AOR (95% CI) Cases/controls AOR (95% CI)
Cigarette smoking 319/1,061 225/670 94/391
Never 103/540 1 52/289 1 51/251 1
Ever 216/521 1.5 (1.02–2.1) 173/381 1.9 (1.2–3.1) 43/140 1 (0.5–1.8)
Regular smoking 206/488 1.5 (1.1–2.2) 163/363 1.9 (1.1–3.1) 43/125 1.1 (0.6–1.9)
Nonregular smoking 10/33 1 (0.4–2.6) 10/18 1.9 (0.6–5.1) 0/15
Duration of smoking
20 years 67/252 1.1 (0.7–1.8) 57/184 1.6 (0.9–2.9) 10/68 0.4 (0.2–1.2)
>20 years 149/269 1.8 (1.2–2.7) 116/197 2.1 (1.2–3.6) 33/72 1.5 (0.7–2.9)
Smoking cigarettes/day
20 cigarettes/day 155/366 1.5 (1.1–2.2) 115/250 1.9 (1.2–3.3) 40/116 1 (0.5–1.9)
>20 cigarettes per day 61/155 1.4 (0.8–2.3) 58/131 1.7 (1–3.2) 3/24 0.8 (0.2–3.1)
Smoked-pack-year
20 pack-year 87/263 1.3 (0.8–1.9) 68/178 1.9 (1.1–3.3) 19/85 0.6 (0.3–1.3)
>20 pack-year 129/258 1.7 (1.1–2.6) 105/203 1.9 (1.1–3.2) 24/55 1.6 (0.8–3.4)
Former smokers
Quit smoking 154/400 1.4 (0.9–2.1) 125/306 1.8 (1.1–2.9) 29/94 0.9 (0.5–1.8)
10 years quit smoking 53/86 1.7 (0.96–3.1) 40/59 2.4 (1.2–4.9) 13/27 1.1 (0.4–2.9)
>10 years quit smoking 101/314 1.3 (0.8–1.9) 85/247 1.7 (0.9–2.8) 16/67 0.8 (0.4–1.8)
1Odds ratios of smoking parameters were adjusted for age, sex, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy
alcohol consumption and family history of cancer in all subjects.–2Odds ratios of smoking parameters, in men and women separately, were adjusted
for age, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy alcohol consumption and family history of cancer.
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control subjects; p 5 0.06). The median and range of cigarettes
smoked per day were identical for patients and control subjects
(median, 20; range, 1–80 cigarettes/day; p 5 0.5). Compared to
nonsmokers, smokers had no signiﬁcant trend in risk for HCC by
number of smoked cigarettes/day. However, when considering
both parameters (years of smoking and number of cigarettes
smoked each day), the median of pack-years was higher for
patients (25.3; range, 0.1–130.0) than for controls (20; range, 0.1–
145.0), p 5 0.06. Men who had quit smoking within 10 years of
diagnosis or recruitment into the study continued to be at a signiﬁ-
cantly increased risk for HCC development.
Noncigarette tobacco products. Table IV shows the distribu-
tion of exposure to chewing tobacco, snuff, pipes and cigars
among case patients and control subjects according to cigarette
smoking status. The proportions of subjects using chewing
tobacco or snuff were higher among control subjects than case
patients. However, pipes and cigars were more frequently used by
case patients than by control subjects. As shown in Table IV, non-
cigarette tobacco products use was not signiﬁcantly associated
with an elevated risk of HCC development. However, heavy use
of pipes and cigars conferred approximately 2.6- and 1.7-fold
increases, respectively, in risk of HCC after controlling for demo-
graphic characteristics and other signiﬁcant risk factors for HCC;
but the association was observed among cigarette smokers and
was not statistically signiﬁcant (p 5 0.07 and 0.09, respectively).
Passive smoking. Because every smoker is involuntarily
exposed to his or her own exhaled and side-stream smoke in the
place where he or she smoked, active smokers (cigarettes, pipe,
cigars and tobacco products) were reclassiﬁed as involuntarily
exposed to others’ mainstream or own exhaled smoke (main-
stream) and side-stream smoke. This categorization may eliminate
the random misclassiﬁcation of passive smoke exposure. Total of
88 HCC patients and 471 control subjects were deﬁned as non-
smokers who never used cigarettes, cigars, pipes, snuff and
tobacco, among whom, 36 HCC patients and 120 control subjects
had no passive smoking exposure. Using these individuals as the
reference group, we estimated the risk of HCC associated with
passive smoking exposure among nonsmokers in the whole popu-
lation and in men and women separately (Table V).
A signiﬁcant difference in passive smoke exposure was
observed between nonsmokers cases (n 5 52, 59.1%) and controls
(n 5 351, 74.5%); p 5 0.002. Such difference is related to the
signiﬁcantly higher exposure of control subjects, compared to case
patients, to passive smoke during childhood (37 cases [42%] and
273 controls [58%], p 5 0.0003). For adulthood exposure, how-
ever, there were no signiﬁcant differences between case patients
(45.5%) and control subjects (53.3%), p 5 0.3.
Among nonsmokers, the exposure time of passive smoking was
similar for exposed case patients and control subjects (mean 6
SE, 24.26 2.5 years for case patients; 26.56 0.7 years for control
subjects) (p 5 0.5). Moreover, Table V shows no signiﬁcant rela-
tionship between the development of HCC and years of exposure
during childhood, adulthood (at home and at work) or total life-
time. Furthermore, subjects who were exposed to passive smoking
had no increased risk of HCC that could be correlated with the age
at ﬁrst exposure or age at cancer diagnosis. The estimated AORs
were 0.5 (95% CI, 0.1–1.9) and 0.6 (95% CI, 0.3–1.1) for patients
who were 50 and >50 years old, respectively, at HCC diagnosis.
Risk modiﬁcation of cigarette smoking by other risk factors
Table VI shows the independent effects of HCV infection, HBV
infection, diabetes mellitus and heavy alcohol consumption, along
with the effect of each risk factor combined with cigarette smok-
ing, on HCC risk in women and men. After adjustment for the
effect of demographic characteristics and other signiﬁcant risk
factors for HCC, there was synergy between cigarette smoking
and HCV infection in men and between cigarette smoking and
heavy alcohol consumption and between cigarette smoking and
HBV infection in women. These interactions ﬁt the assumption of
additive scales. When the AOR was used as an estimate of the rel-
ative risk of disease development, the relative excess risk for
patients with a history of cigarette smoking along with HCV posi-
tivity in men or along with heavy alcohol consumption in women
exceeded the sum of the relative excess risks for each risk factor
alone [e.g., 136.3 2 1.0 > (1.8 2 1.0) 1 (28.9 2 1.0)]. The esti-
mated synergism index (S) was 4.7 (95% CI, 2.8–6.6) for smoking
and HCV in men and 5.8 (95% CI, 2.4–9.2) for smoking and
heavy alcohol consumption in women. However, for HBV and
smoking in women, the S index was not signiﬁcant (2.6; 95% CI,
0.8–4.4). No risk modiﬁcation between smoking and other risk
factors was observed in men or women.
Discussion
The results of this large case-control study conﬁrm the signiﬁ-
cance of previously reported risk factors for HCC development,
including heavy alcohol consumption, diabetes mellitus, family
history of cancer and chronic HCV and HBV infection. Also
TABLE IV – USE OF NONCIGARETTE TOBACCO PRODUCTS AND RISK FOR HCC: AOR (95% CI)1 USING MULTIVARIABLE LOGISTIC REGRESSION
Smoking variable
Total population Cigarette smokers Noncigarette smokers
Cases/controls AOR (95% CI) Cases/controls AOR (95% CI) Cases/controls AOR (95% CI)
Chewing tobacco 319/1,061 216/521 103/540
Never use 305/994 1 203/480 1 102/514 1
Ever use 14/67 0.7 (0.3–1.4) 13/41 0.9 (0.4–2.1) 1/26 0.2 (0.02–1.9)
Low or moderate intake2 9/39 0.9 (0.4–2.2) 8/30 1.2 (0.5–2.9) 1/9 0.3 (0.02–3.9)
High intake3 5/28 0.2 (0.04–1.2) 5/11 0.3 (0.1–2.1) 0/17
Snuff
Never use 310/1,009 1 208/492 1 102/517 1
Ever use 9/52 0.5 (0.2–1.2) 8/29 0.5 (0.2–1.5) 1/23 0.2 (0.02–2.3)
Low or moderate intake2 8/24 0.8 (0.3–2.3) 7/16 0.9 (0.3–2.8) 1/8 0.4 (0.03–5.1)
High intake3 1/28 0.1 (0.01–1) 1/13 0.1 (0.03–1) 0/15
Pipe
Never use 292/996 1 195/474 1 97/522 1
Ever use 27/65 1.4 (0.8–2.6) 21/47 1.5 (0.9–3) 6/18 1.5 (0.4–5.3)
Low or moderate intake2 17/50 1.2 (0.6–2.5) 13/37 1.2 (0.5–2.7) 4/13 1.7 (0.4–7.1)
High intake3 10/15 2 (0.7–5.6) 8/10 2.6 (0.9–8.2) 2/5 1.2 (0.1–11.2)
Cigars
Never use 285/976 1 189/462 1 96/514 1
Ever use 34/85 1.5 (0.9–2.5) 27/59 1.6 (0.9–2.8) 7/26 1.4 (0.4–4.7)
Low or moderate intake2 28/74 1.5 (0.9–2.8) 23/53 1.3 (0.8–2.1) 5/21 1.6 (0.4–6.1)
High intake3 6/11 1.2 (0.3–4.3) 4/6 1.7 (0.9–2.9) 2/5 0.9 (0.1–10.1)
1Adjusted odds ratios for age, sex, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy alcohol consumption, cigarette
smoking and family history of cancer.–2Low or moderate intake:20 intake-years of exposure.–3High intake:>20 intake-years of exposure.
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consistent with previous studies, smoking-related HCC was signif-
icant among men.4,10,35,36 Moreover, it appeared that the magni-
tude of AOR for HCC risk was larger with smoking duration than
with the intensity of smoking; this may, in part, reﬂect the accu-
racy with which these 2 parameters were measured. While the du-
ration of smoking can be reasonably accurately measured in epide-
miological studies, the intensity of smoking is subject to misclassi-
ﬁcation bias. Intensity is inﬂuenced not only by the number of
cigarettes per day but also by the depth of inhalation and number
of puffs taken per cigarette. It is possible that smokers compensate
for a reduction in the number of cigarettes smoked per day by
smoking each cigarette more intensively.21 The same ﬁnding was
observed for the association between cigarette smoking and lung
cancer.21,37 In addition, we found that the excess risk persisted
among men who had quit smoking 10 or fewer years before the
study, independent of the presence of other signiﬁcant risk factors.
This ﬁnding supports the results of early Japanese reports14,36 and
a U.S. military veterans study38,39 in which a positive association
was found between former smoking and liver cancer.
The exact mechanism of tobacco hepatocarcinogenesis is
unknown; however, of approximately 4,000 components identiﬁed
in tobacco smoke, at least 55 are known carcinogens. The major
chemical carcinogens include polycyclic aromatic hydrocarbons,
such as benzo[a]pyrene; aromatic amines, such as 4-aminobi-
phenyl; and nitrosamines, such as 4-(methylnitrosamine)-1-(3-pyr-
idyl)-1-butanone. A case control study demonstrated that 4-amino-
biphenyl DNA adducts contained in tobacco smoke is a liver
carcinogen.40 In addition, tobacco smoke contains volatile
compounds (e.g., benzene), radioactive elements (e.g., polonium-
210) and free radicals that may also play a role in hepatocarcino-
genicity.41,42
TABLE VI – RISK MODIFICATION OF CIGARETTE SMOKING BY OTHER RISK FACTORS. AOR (95% CI) USING MULTIVARIABLE LOGISTIC REGRESSION
Variables
Men Women
Cases/controls AOR (95% CI) Cases/controls AOR (95% CI)
HCV Smoking 225/540 Model (1)1 94/349 Model (1)1
No No 40/229 1 45/222 1
Yes No 12/3 28.9 (7.3–114.2) 6/2 13.4 (2.3–78.8)
No Yes 104/304 1.8 (1.1–2.9) 30/125 1.2 (0.6–2)
Yes Yes 69/4 136.3 (43.2–429.6) 13/0
HBV2 Smoking 225/540 Model (2)3 94/349 Model (2)3
No No 39/225 1 42/217 1
Yes No 13/7 9.7 (3.3–28.7) 9/7 3.1 (1.1–10.1)
No Yes 132/298 2 (1.2–3.3) 35/119 1.1 (0.6–1.9)
Yes Yes 41/10 9.6 (3.9–2.4) 8/6 6.7 (1.9–24.1)
Heavy drinking Smoking 117/262 Model (3)4 66/266 Model (3)4
No No 28/121 1 38/184 1
Yes No 9/13 3.9 (1.1–14.9) 1/3 3.1 (0.3–35.8)
No Yes 30/84 1.5 (1.1–3.4) 18/74 1.1 (0.5–2.3)
Yes Yes 50/44 2.8 (1.2–6.8) 9/5 13.7 (3.2–57.9)
Diabetes mellitus Smoking 225/670 Model (4)5 94/391 Model (4)5
No No 30/260 1 37/233 1
Yes No 22/29 8.4 (3.6–19.8) 14/18 4 (1.6–9.8)
No Yes 110/326 2.4 (1.3–4.2) 34/133 1.2 (0.7–2.3)
Yes Yes 63/55 9.1 (4.6–17.9) 9/7 4.6 (1.3–15.9)
1Adjusted OR for age, race, education, marital status, state of residency, family history of cancer, HBV, diabetes and alcohol.–2HBV includes
HBsAg1 or Anti-HBc1.–3Adjusted OR for age, race, education, marital status, state of residency, family history of cancer, HCV, diabetes and
alcohol.–4Adjusted OR for age, race, education, marital status, state of residency, family history of cancer, HCV, HBV and diabetes.–5Adjusted
OR for age, race, education, marital status, state of residency, family history of cancer, HCV, HBV and alcohol.
TABLE V – PASSIVE SMOKING EXPOSURE AND RISK FOR HCC AMONG NONSMOKERS: AOR (95% CI)1 USING MULTIVARIABLE LOGISTIC REGRESSION
None-smoking variable
Total population Men Women
Cases/controls1 AOR (95% CI) Cases/controls AOR (95% CI) Cases/controls AOR (95% CI)
Passive smoking exposure 88/471 41/224 47/247
Never 36/120 1 19/60 1 17/60 1
Childhood only 12/100 0.4 (0.2–1.1) 7/55 0.1 (0.02–0.5) 5/45 0.6 (0.2–1.9)
Adulthood only 15/78 0.6 (0.3–1.4) 6/40 0.2 (0.1–1.1) 9/38 0.9 (0.3–2.5)
Childhood and adulthood 25/173 0.6 (0.3–1.1) 9/69 0.3 (0.1–1.2) 16/104 0.7 (0.3–1.5)
Childhood exposure 37/273 16/124 21/149
Occasional 1/52 0.2 (0.02–1.2) 0/27 1/25 0.3 (0.03–2.5)
Regular 36/221 0.6 (0.3–1.1) 16/97 0.3 (0.1–1.1) 20/124 0.7 (0.3–1.7)
10 years 3/40 0.4 (0.1–1.7) 1/19 0.4 (0.03–4.9) 2/21 0.4 (0.1–2.4)
>10 years 34/233 0.6 (0.3–1.2) 15/105 0.2 (0.1–0.8) 19/128 0.8 (0.3–1.7)
Adulthood exposure2 40/251 15/109 25/142
Occasional 3/87 0.1 (0.02–05) 2/52 0.1 (0.02–0.6) 1/35 0.1 (0.01–1.5)
Regular 37/164 0.9 (0.4–1.7) 13/57 0.6 (0.2–2.5) 24/107 1 (0.4–2.2)
20 years 27/136 0.8 (0.4–1.6) 13/58 0.5 (0.1–2.1) 14/78 1 (0.4–2.4)
>20 years 13/115 0.4 (0.2–1.3) 2/51 0.1 (0.01–1.1) 11/64 0.7 (0.3–1.8)
Lifetime exposure 52/351 22/164 30/187
Occasional 4/83 0.2 (0.1–0.9) 2/47 0.1 (0.01–0.6) 2/36 0.3 (0.1–1.6)
Regular 48/268 0.6 (0.3–1.1) 20/117 0.2 (0.1–0.8) 28/151 0.8 (0.4–1.7)
20 years 23/183 0.4 (0.2–0.9) 13/93 0.1 (0.02–0.6) 10/90 0.6 (0.2–1.5)
>20 years 29/168 0.7 (0.3–1.3) 9/71 0.3 (0.1–1.1) 20/97 0.8 (0.4–1.9)
1Adjusted odds ratios for age, sex, race, education, marital status, state of residency, HCV, HBV, diabetes, heavy alcohol consumption and
family history of cancer.–2Adult exposure estimated from summation of exposure years during adulthood at home and at work exclusive from
childhood period.
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Unlike cigarette smoking, the magnitude of AOR for the associ-
ation between heavy alcohol consumption and HCC was larger in
women than in men, which may be partially attributable to the
synergism between female sex and heavy alcohol consumption. A
recent review by Mancinelli et al.43 suggested that women may
experience a more rapid progression of alcohol damage than men.
The lower body mass index and body ﬂuid content in women than
men may contribute to lowered ethanol diffusion and high blood
concentration in women.44 Moreover, the activity of gastric alco-
hol dehydogenase, which is responsible for the ﬁrst-pass metabo-
lism of ethanol in the stomach, is signiﬁcantly lower in women
than in men, which implies that large amounts of alcohol will be
metabolized by hepatic alcohol dehydogenase.45,46 It is also possi-
ble that genetic variations in carcinogen metabolism, inﬂamma-
tory response, DNA repair and cell-cycle regulation play a role
in determining individual susceptibility to tobacco and alcohol
carcinogenesis, which may partially explain variations in HCC
risk by sex.
The most notable ﬁndings of the current study were the synergy
between cigarette smoking and HCV in men and cigarette smok-
ing and heavy alcohol consumption in women on the etiology of
HCC. An increased risk of HCC associated with cigarette smoking
was previously reported for chronic carriers of HBV10 and
HCV5,12 and for alcohol drinkers.11,16 The mechanisms by which
cigarette smoking enhances the HCC risk associated with HCV
infection or alcohol consumption are unknown. However, it is pos-
sible that, in some people with these risk factors, smoking-induced
oxidative stress increases the liver’s susceptibility to chronic
inﬂammation, DNA damage and HCC development. A direct
effect of smoking that promotes the rapid progression of HCV- or
alcohol-induced cirrhosis cannot be excluded.
Despite the signiﬁcant association between cigarette smoking
and the risk of HCC, we found no signiﬁcant association between
the risk of HCC and passive smoking. Few studies have examined
the relationship between passive smoking and cancer. Except for
lung cancer, the evidence for an association between passive
smoking and several types of cancer is inconclusive. The lack of
risk association between passive smoking and HCC in women was
consistent with the results of Nishino et al.,47 who reported no sig-
niﬁcant increase in the relative risk of liver cancer among women
whose husbands smoked (relative risk, 1.2; 95% CI, 0.5–3.2). To
our knowledge, no previous studies have explored this risk in
men. Our observed inverse association between HCC development
and adulthood exposure to passive smoking in men has been pre-
viously reported for breast cancer development.47 A possible
explanation for this ﬁnding could be attributed to chance or to re-
sidual confounding of unmeasured protective factors, such as die-
tary intake of fruits and vegetables, vitamins, physical activity and
normal body weight among nonsmokers exposed to others’ smoke.
In addition, potential selection bias related to the use of hospital
visitors as control subjects is also possible. Because the control
subjects were companions of cancer patients, there is a possibility
that the prevalence of passive smoking among control subjects
was higher than general population. However, it is unlikely that
any association between passive smoking and HCC risk was
masked by selection bias in our study, for the following reasons.
We found a positive association between active smoking and
HCC. In addition, our control recruitment excluded subjects who
were accompanying patients with cancers that are strongly associ-
ated with cigarette smoking (e.g., lung and head and neck can-
cers). As a result, the prevalence of passive smoking exposure
among noncigarette smoking control subjects was comparable to
that reported for U.S. adults by other population-based stud-
ies.29,48 Moreover, comparing the current controls with other can-
cers (smoking-unrelated), revealed no signiﬁcant effect of smok-
ing on these cancers. Until other epidemiological studies conﬁrm
our ﬁnding, the lack of risk-relationship between HCC and passive
smoking should be interpreted with caution.
The use of chewing tobacco and snuff was also not related to
HCC development in general or in nonsmokers. However, a poten-
tial risk of HCC for heavy users of pipes and cigars may exist
among cigarette smokers. To our knowledge, our study is the ﬁrst
to explore the association between the use of noncigarette prod-
ucts or passive smoking and the risk of HCC after taking into con-
sideration the confounding effect of known HCC risk factors. We
also assessed both the intensity and duration of exposure during
different life periods. The observed moderate association of heavy
pipe and cigar use with HCC is not surprising, given the previ-
ously reported high mortality rate from liver cancer among cigar
users39,49; however, the previous reports did not adjust for major
HCC risk factors, particularly viral hepatitis. With respect to
chewing tobacco, we found no previous epidemiological study
that investigated any relationship between chewing tobacco and
HCC. However, an association between HCC and chewing betel
quid,50,51 a common habit in Taiwan52 has been reported.
It is generally accepted that accurately assessing the relation-
ship between noncigarette tobacco use and cancer risk is difﬁcult.
Obstacles include the lack of standard measurements for cigar size
and tobacco type, variations in the behavior of people using these
types of products (inhalation versus chewing), the low prevalence
of noncigarette tobacco exposure in the general population (com-
pared to the marked prevalence of cigarette smoking) and the
potential confounding effect of high socioeconomic status among
cigar and pipe users. All of these factors may bias measurements
of the cumulative intake of noncigarette tobacco products. In our
study, however, we were able to assess several smoking types
with proper adjustment for confounding factors. Both HCC
patients and control subjects were personally interviewed using a
structured and validated questionnaire for several sources of
smoke exposure.
The study was speciﬁcally designed to minimize ascertainment
or selection biases related to misdiagnosis of the case patients. All
of our case patients had pathologically conﬁrmed HCC, and both
case patients and control subjects were prospectively enrolled
simultaneously at M. D. Anderson Cancer Center. Moreover, we
believe that our control selection was appropriate and representa-
tive of our study base. Control subjects were cancer-free at the time
of enrollment and less likely than case patients to have cancer,
chronic illness or previous exposure to tobacco and alcohol use.
Moreover, all spouses of other cancers in the control group reported
that they would have chosen to be referred to the same hospital if
they had been diagnosed with cancer during the same time period,
probably because spouses tend to share the same family physician,
have the same health insurance coverage, and live in the same geo-
graphic location. Moreover, altruism was the main reason given by
controls for accompanying cancer patients during hospital visit. It
is unlikely that such reason is related to the exposures under inves-
tigation by the current study. All of these results indicated that the
patients and control subjects had the same catchments, which fur-
ther supports the idea that the study control subjects were represen-
tative of the hospital (M. D. Anderson Cancer Center) population
from which the case patients were selected.53–55
In conclusion, in this American hospital-based case-control
study, after adjusting for other known risk factors for HCC, we did
not ﬁnd signiﬁcant associations between passive smoking or use
of noncigarette tobacco products and risk of HCC among non-
smokers. However, sex differences were observed in HCC rela-
tionship with cigarette smoking and alcohol consumption. We did
ﬁnd a signiﬁcant association between HCC and cigarette smoking
in men and heavy alcohol consumption in women. A synergistic
interaction between cigarette smoking and HCV and cigarette
smoking and alcohol consumption was observed for men and
women, respectively. The observed sex difference in HCC devel-
opment could be attributed to genetic variation between men and
women with different susceptibility to HCC development upon
their environmental exposure to smoking and alcohol. However,
these ﬁndings need to be conﬁrmed in different populations. In the
meantime, control of all sources of smoking exposure would
appear to be a prudent approach for the prevention of HCC, espe-
cially in patients with chronic hepatitis infections.
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